TL;DRAbstract
This is a review of the discovery and development of C225/Cetuximab, a novel monoclonal antibody (mAb) treatment for cancer. Cetuximab was the first anticancer agent that successfully targeted a receptor for a growth factor and a protein tyrosine kinase. Blocking the signaling activity of the epidermal growth factor (EGF) receptor represented a new targeted approach to cancer therapy. Preclinical studies with human cancer xenografts suggested that C225 worked best in combination with chemotherapy or radiation. Many possible mechanisms of action have been uncovered, including inhibition of each of the six characteristics of a cancer cell described by Hanahan and Weinberg (1). The research on C225 over a period of two decades has involved dozens of academic collaborations, numerous grants from the National Cancer Institute, and the work of four pharmaceutical/biotech companies. There was a setback in the Food and Drug Administration (FDA) review process, but approval for clinical use in
Chat with Paper
AI Agents for this Paper
This is a review of the discovery and development of C225/Cetuximab, a novel monoclonal antibody (mAb) treatment for cancer. Cetuximab was the first anticancer agent that successfully targeted a receptor for a growth factor and a protein tyrosine kinase. Blocking the signaling activity of the epidermal growth factor (EGF) receptor represented a new targeted approach to cancer therapy. Preclinical studies with human cancer xenografts suggested that C225 worked best in combination with chemotherapy or radiation. Many possible mechanisms of action have been uncovered, including inhibition of each of the six characteristics of a cancer cell described by Hanahan and Weinberg (1). The research on C225 over a period of two decades has involved dozens of academic collaborations, numerous grants from the National Cancer Institute, and the work of four pharmaceutical/biotech companies. There was a setback in the Food and Drug Administration (FDA) review process, but approval for clinical use in
Chat
Click to start Chat